Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 05/20/2025 12:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock STAB vs. SCPS, EVLO, GNCAQ, GNCA, ARDS, AMPE, CALA, CMRA, EFTR, and CLVRShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), and Clever Leaves (CLVR). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Calithera Biosciences Comera Life Sciences eFFECTOR Therapeutics Clever Leaves Statera Biopharma (NASDAQ:STAB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media refer more to STAB or SCPS? In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Statera Biopharma Neutral Scopus BioPharma Neutral Which has higher valuation and earnings, STAB or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Which has more volatility and risk, STAB or SCPS? Statera Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Is STAB or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Scopus BioPharma N/A N/A N/A Does the MarketBeat Community favor STAB or SCPS? Scopus BioPharma received 2 more outperform votes than Statera Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformStatera BiopharmaN/AN/AScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes SummaryStatera Biopharma and Scopus BioPharma tied by winning 1 of the 2 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A8.9726.6219.77Price / SalesN/A253.27392.02116.56Price / CashN/A65.8538.2534.62Price / BookN/A6.486.814.53Net IncomeN/A$143.98M$3.23B$248.18M7 Day PerformanceN/A3.37%4.05%1.06%1 Month PerformanceN/A7.83%11.64%14.68%1 Year PerformanceN/A-2.24%17.11%6.87% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020SCPSScopus BioPharmaN/A$0.00flatN/A-85.7%$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A+0.0%$6,000.00N/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-98.7%$3,000.00N/A0.0020Analyst ForecastGap UpCALACalithera BiosciencesN/A$0.00+500.0%N/A-97.0%$3,000.00N/A0.0060Analyst ForecastGap UpCMRAComera Life SciencesN/AN/AN/AN/A$3,000.00$1.00M0.002EFTReFFECTOR TherapeuticsN/A$0.00+200.0%N/A-100.0%$3,000.00$3.55M0.0010Upcoming EarningsCLVRClever LeavesN/A$0.00+100.0%N/A-100.0%$1,000.00$17.42M0.00560 Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors Calithera Biosciences Competitors Comera Life Sciences Competitors eFFECTOR Therapeutics Competitors Clever Leaves Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STAB Stock Free STAB Stock Alerts